Skip to main content

Virgin Hotels Las Vegas Uses Nanotechnology for Surface Disinfection and Protection

a group of people standing in front of a building
NanoClean Team March 16, 2021, Pre-Grand Opening of Virgin Hotels Las Vegas From left: Steve Wilkinson, Dan Wilkinson, Grady Enos, Christopher Rafferty and NanoVapor Biotech CEO Fernando Lehrer.

NanoVapor Biotech (NVB), an innovator in self-disinfecting surface protection technology, announced today that it was chosen by Virgin Hotels Las Vegas, part of Curio Collection by Hilton, to treat their hotel and casino with its proprietary 90-Day Surface Protection Treatment System™ powered by OMNISOL, an anti-microbial solution that is 100% environmentally friendly and lasts longer than regular disinfectants. The treatment provides antimicrobial surface disinfection, and protection, that remains active for up to 90 days.

Known for its long-acting technology, NVB's 90-Day Surface Protection Treatment System™ powered by OMNISOL has been relied on to disinfect and protect surfaces in settings such as medical facilities, public transportation, schools, government offices, shopping centers, casinos, theaters, and churches, among others.

"We are committed to taking every precaution at Virgin Hotels Las Vegas to protect our guests and team members from the risks of COVID-19 or any other harmful viruses or diseases.  NanoVapor Biotech gives me the confidence that we are providing the best quality protection available," said Richard "Boz" Bosworth, President & CEO of JC Hospitality and Owner of Virgin Hotels Las Vegas

NanoVapor Biotech's 90-Day Surface Protection Treatment System™ powered by OMNISOL utilizes EPA-registered, highly effective non-toxic solution to ensure complete coverage and continued persistence over the 90-day treatment period. "Our long-lasting solution has been applied to high-touch surfaces throughout the hotel in spaces like restaurants, meeting rooms, lobbies, casino tables and chairs, bars, spa and wellness center, bathrooms and public social gathering areas, with incredibly high levels of success, as measured by our regular monitoring" said Fernando Lehrer, CEO of NanoVapor Biotech.

This ad will auto-close in 10 seconds